Adalimumab biosimilar - Coherus BioSciences

Drug Profile

Adalimumab biosimilar - Coherus BioSciences

Alternative Names: CHS-1420

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 02 Mar 2017 Coherus Biosciences completes a phase I pharmacokinetic trial for Plaque psoriasis (In volunteers) in USA prior to March 2017
  • 02 Mar 2017 Coherus Biosciences initiates a phase I pharmacokinetic trial for Plaque psoriasis (In volunteers) in USA prior to March 2017
  • 01 Mar 2017 Coherus Biosciences completes the phase III PsOsim trial in Plaque psoriasis in USA, Latvia, Estonia, Poland, Croatia, and Slovakia (NCT02489227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top